Entering the era of prenatal gene therapies
In February 2025, researchers at St Jude Children’s Research Hospital reported the first known in utero use of Roche’s spinal…
30 Apr 2025
Magazine: The GLP-1 shortage is over. What’s next for compounders?
The astronomical rise in popularity of GLP-1RAs in recent years has led to a shortage, prompting users to turn to compounders as an alternative to the likes of Novo Nordisk’s…
30 Apr 2025
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a common side effect of weight loss treatments. In recent years,…
23 Apr 2025
FDA layoffs and priority review programme’s lapse disrupt rare disease pipeline
Against the stark backdrop of the FDA job cuts, stakeholders in the rare disease space find themselves facing heightened uncertainty. In late March 2025, the Trump administration moved forward with…
16 Apr 2025
The GLP-1 drug shortage is over. What’s next for the compounders?
“I am taking compounded semaglutide that I ordered online, but I don’t know how long I will have access to it.” That was what one anonymous patient told Pharmaceutical Technology…
11 Apr 2025
Can AI replace medical writers? Experts say not immediately
Artificial intelligence (AI) is said to be exponentially faster and effective at writing lengthy and complex clinical trial documents, but those using the technology see some limitations, which could mean…
09 Apr 2025
IRA holds the scope to shape pharma’s research strategy, say experts
Pharma companies will need to rethink business and research and development (R&D) strategies to mitigate against the global impact that will be felt from the US Government’s Inflation Reduction Act…